805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment

Andrew R. Clamp, Jonathan A. Ledermann(Cancer Institute (WIA)), Mahesh Parmar(University College London), Adrian Cook(University College London), Timothy Perren(Royal Marsden NHS Foundation Trust), James D. Brenton(University of Cambridge), Andrew Dean, Richard Kaplan(University College London), Sudha Sundar(Sandwell & West Birmingham Hospitals NHS Trust), Sarah P. Blagden(Churchill Hospital), Elizabeth C James(MRC Clinical Trials Unit at UCL), Ann Marie Swart(University of East Anglia), Raj Naik(Queen Elizabeth Hospital), Jonathan Badrock(MRC Clinical Trials Unit at UCL), Iain A. McNeish(Beatson West of Scotland Cancer Centre), JW Kim(Seoul National University Hospital), Dearbhaile M. O’Donnell, C. Coyle(MRC Clinical Trials Unit at UCL), Jane Hook(University of Leeds), Dolores Gallardo‐Rincón(Instituto Nacional de Cancerología)
Annals of Oncology
September 1, 2020
10.1016/j.annonc.2020.08.944
Cited by 4

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k